NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (AMEX: ELI) has entered into a development agreement with The PharmaNetwork, LLC (“TPN”). Elite and TPN expect to co-develop and commercialize a generic version of a synthetic narcotic analgesic drug, and upon completion of development, intend to license it for sale.
